Marzena Walkiewicz
Overview
Explore the profile of Marzena Walkiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Helman G, Takanohashi A, Hagemann T, Perng M, Walkiewicz M, Woidill S, et al.
Hum Mutat
. 2022 Aug;
43(9):1344.
PMID: 35920398
No abstract available.
2.
Richardson Z, Deleage C, Tutuka C, Walkiewicz M, Del Rio-Estrada P, Pascoe R, et al.
J Immunol Methods
. 2021 Dec;
501:113198.
PMID: 34863818
The main barrier to a cure for HIV is the persistence of long-lived and proliferating latently infected CD4 T-cells despite antiretroviral therapy (ART). Latency is well characterized in multiple CD4...
3.
Van Bergen N, Bell K, Carey K, Gear R, Massey S, Murrell E, et al.
Hum Mol Genet
. 2021 Sep;
31(3):362-375.
PMID: 34494102
The nuclear pore complex (NPC) is a multi-protein complex that regulates the trafficking of macromolecules between the nucleus and cytoplasm. Genetic variants in components of the NPC have been shown...
4.
Arulananda S, OBrien M, Evangelista M, Harris T, Steinohrt N, Jenkins L, et al.
Cell Death Discov
. 2021 Jun;
7(1):146.
PMID: 34131107
No abstract available.
5.
Helman G, Taylor L, Walkiewicz M, Le Moing M, Eggers S, Yaplito-Lee J, et al.
Eur J Med Genet
. 2021 Jun;
64(8):104259.
PMID: 34126256
RNA sequencing (RNAseq) is emerging as a complementary tool to DNA sequencing, providing utility in diagnosis for disorders such as neuronal ceroid lipofuscinosis CLN2 disease. We describe an individual with...
6.
Arulananda S, OBrien M, Evangelista M, Jenkins L, Poh A, Walkiewicz M, et al.
Cell Death Discov
. 2021 May;
7(1):122.
PMID: 34050131
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell...
7.
Chia P, Parakh S, Russell P, Gan H, Asadi K, Gebski V, et al.
Lung Cancer
. 2021 Jan;
153:35-41.
PMID: 33453471
Aim: Conformational forms of the epidermal growth factor receptor (EGFR) are pro-tumorigenic. The prevalence and impact of conformational forms of EGFR in malignant mesothelioma (MM) is unknown. We investigated expression...
8.
Arulananda S, OBrien M, Evangelista M, Harris T, Steinohrt N, Jenkins L, et al.
Cell Death Discov
. 2020 Dec;
6(1):114.
PMID: 33298868
Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a decade. Standard-of-care treatment relies...
9.
Helman G, Compton A, Hock D, Walkiewicz M, Brett G, Pais L, et al.
Hum Mutat
. 2020 Nov;
42(1):19-24.
PMID: 33169436
The diagnosis of Mendelian disorders following uninformative exome and genome sequencing remains a challenging and often unmet need. Following uninformative exome and genome sequencing of a family quartet including two...
10.
Chia P, Russell P, Asadi K, Thapa B, Gebski V, Murone C, et al.
Lung Cancer
. 2020 Oct;
150:1-8.
PMID: 33035778
Background: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other mesothelial membranes. Agents targeting vascular endothelial growth factor (VEGF) such as bevacizumab; and multi-kinase inhibitors such as...